454 was the first of the NGS platforms on the market, launching in 2005. It was acquired by Roche in 2007 who, in October 2013, announced that they were shutting down the business by mid-2016. What is listed below are the final stats for the machines. Genome Sequencer FLX+ The GS FLX System is 454′s […]
Sequencing companies are born and sequencing companies die. Or get acquired. Or just change their names. We honor those that have come before us.
Status: No longer developing NGS platform Back in 2008 Affymetrix stated that they would start developing a chip combining DNA capture and enzymatic-based sequencing. While it is unclear how far along this technology was developed, Affymetrix has never released such a product and has since stated that they are not going to directly enter the […]
Status: technology sold off Agencourt Bioscience was developing a ‘sequencing-by-ligation’ system when they were acquired by Beckman in 2005. Beckman retained the sequencing services business, while Agencourt Personal Genomics was spun out to continue developing the NGS platform technology. APG was then acquired by ABI (now called Life Technologies) in 2006 for $120M. APG’s technology […]
Status: acquired Avantome was co-founded in 2008 by Mostafa Ronaghi, a co-inventor of the pyrosequencing technology. They were working on the development of a low cost, long read system based on pyrosequencing technology when they were acquired by Illumina in 2008 for $60M. Illumina purchased the technology to complement their sequencing portfolio and to form […]
Status: name change BioNanomatrix changed their name to BioNano Genomics in 2011. Please contact us at firstname.lastname@example.org if you have any information or opinions you’d like to share about this page.
Complete Genomics was acquired by the Chinese company BGI in 2013, and in 2018 became part of MGI, a subsidiary of BGI. The information below is from just prior to the acquisition. General Overview Complete Genomics is unique in the NGS market in that instead of selling their proprietary instrumentation they use it to offer […]
Status: ceased operations Genizon Biosciences was developing sequencing technology based on ‘sequencing-by-hybridization’ of rolling circle amplicons. The technology was never launched and the company ceased operations in 2011. Please contact us at email@example.com if you have any information or opinions you’d like to share about this page.
GnuBio was acquired by Bio-Rad in 2014 and was effectively closed down in 2017 when Bio-Rad shuttered the original GnuBio facility in Cambridge, MA. The information below is from early 2015. Having backed off their initial business model of offering 30x human genome coverage for $30 (that’s thirty dollars, not $30k) and a […]
Halcyon Molecular was developing a system based on electron microscopy. The system was intended to work by stretching out very long individual molecules of DNA (up to 150kb) and staining them with contrast agents, allowing for the determination of individual bases with an electron microscope. When founded in 2009, the company claimed to be aiming […]
General Overview Intelligent Bio-Systems had been developing their sequencing-by-synthesis (SBS) chemistry, which it licensed exclusively from Jengyue Ju and Columbia University, since 2006. In 2011 they released their first next-gen sequencer, the MAX-Seq, through a collaboration with Danaher Motion’s Dover and Azco Biotech. With the acquisition of IBS by Qiagen in 2012, the company may […]